Show simple item record

Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas.

dc.contributoren-US
dc.contributorNo se recibieron fondos ni colaboraciones para la elaboración de este manuscrito.es-ES
dc.creatorDanza, Alvaro; 1. Unidad Docente Asistencial en Enfermedades Autoinmunes Sistémicas y Reumatológicas. Clínica Médica, Departamento de Medicina, Hospital Pasteur, Administración de Servicios de Salud del Estado (ASSE). Facultad de Medicina, Universidad de la República. Montevideo, Uruguay. 2. Unidad de Investigación de Enfermedades Autoinmunes. Servicio de Medicina Interna. BioCruces Health Research Institute. Hospital Universitario Cruces. Universidad del País Vasco (UPV) / Euskal Herriko Unibertsitatea (EHU). Barakaldo, España.
dc.creatorGraña, Diego; Unidad Docente Asistencial en Enfermedades Autoinmunes Sistémicas y Reumatológicas. Clínica Médica, Departamento de Medicina, Hospital Pasteur, Administración de Servicios de Salud del Estado (ASSE). Facultad de Medicina, Universidad de la República. Montevideo, Uruguay.
dc.creatorGoñi, Mabel; Unidad Docente Asistencial en Enfermedades Autoinmunes Sistémicas y Reumatológicas. Clínica Médica, Departamento de Medicina, Hospital Pasteur, Administración de Servicios de Salud del Estado (ASSE). Facultad de Medicina, Universidad de la República. Montevideo, Uruguay.
dc.creatorVargas, Andrea; 1. Unidad Docente Asistencial en Enfermedades Autoinmunes Sistémicas y Reumatológicas. Clínica Médica, Departamento de Medicina, Hospital Pasteur, Administración de Servicios de Salud del Estado (ASSE). Facultad de Medicina, Universidad de la República. Montevideo, Uruguay. 2. Cátedra de Reumatología. Facultad de Medicina, Universidad de la República. Montevideo, Uruguay.
dc.creatorRuiz-Irastorza, Guillermo; Unidad de Investigación de Enfermedades Autoinmunes. Servicio de Medicina Interna. BioCruces Health Research Institute. Hospital Universitario Cruces. Universidad del País Vasco (UPV) / Euskal Herriko Unibertsitatea (EHU). Barakaldo, España.
dc.date2016-01-18
dc.date.accessioned2019-11-11T18:27:39Z
dc.date.available2019-11-11T18:27:39Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4338
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/111242
dc.descriptionHydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. It has immunomodulatory, hypolipidemic, hypoglycemic and antithrombotic properties and it diminishes the risk of malignancies. The most important mechanisms to explain the immunomodulatory actions are its ability to reduce inflammatory pathways and Toll-like receptors activation. The safety profile is favorable. In spite of its low frequency, retinal toxicity is potentially severe. In systemic lupus erythematous HCQ therapy reduces activity, the accrual of organ damage, risk of infections and thrombosis and improves the cardiometabolic profile. It contributes to induce lupus nephritis remission, spares steroid use and increases survival rates. In rheumatoid arthritis, it improves cardiometabolic risk and has a favorable effect in joint inflammation. In Sjögren’s syndrome, an increased lacrimal quality as well as an improvement in objective and subjective inflammatory markers has been demonstrated with HCQ. In Antiphospholipid Syndrome, HCQ is effective in primary and secondary thrombosis prevention. The effectiveness of the drug in other systemic autoimmune diseases is less established. HCQ therapy may improve dermatological manifestations in Dermatomyositis and may have a positive effects in the treatment of Sarcoidosis and Still disease.en-US
dc.descriptionHydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. It has immunomodulatory, hypolipidemic, hypoglycemic and antithrombotic properties and it diminishes the risk of malignancies. The most important mechanisms to explain the immunomodulatory actions are its ability to reduce inflammatory pathways and Toll-like receptors activation. The safety profile is favorable. In spite of its low frequency, retinal toxicity is potentially severe. In systemic lupus erythematous HCQ therapy reduces activity, the accrual of organ damage, risk of infections and thrombosis and improves the cardiometabolic profile. It contributes to induce lupus nephritis remission, spares steroid use and increases survival rates. In rheumatoid arthritis, it improves cardiometabolic risk and has a favorable effect in joint inflammation. In Sjögren’s syndrome, an increased lacrimal quality as well as an improvement in objective and subjective inflammatory markers has been demonstrated with HCQ. In Antiphospholipid Syndrome, HCQ is effective in primary and secondary thrombosis prevention. The effectiveness of the drug in other systemic autoimmune diseases is less established. HCQ therapy may improve dermatological manifestations in Dermatomyositis and may have a positive effects in the treatment of Sarcoidosis and Still disease.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4338/1830
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19070
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19071
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19081
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19082
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19083
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19084
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19085
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/19121
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/20585
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4338/20586
dc.sourceRevista Médica de Chile; Vol. 144, núm. 2 (2016): FEBRERO 2016es-ES
dc.source0034-9887
dc.subjectAntiphospohlipid syndrome; Autoimmune diseases; Hydroxychloroquine, systemic lupus erythematosus; Rheumatoid arthritis; Sjögren’s syndromeen-US
dc.subjectAntiphospohlipid syndrome; Autoimmune diseases; Hydroxychloroquine, systemic lupus erythematosus; Rheumatoid arthritis; Sjögren’s syndromees-ES
dc.titleHYDROXYCHLOROQUINE FOR AUTOIMMUNE DISEASESen-US
dc.titleHidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas.es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record